ConductScience.org, home

Paper42014686

A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial.

Liu H and 10 others. Nat Commun, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial. Papers, record 42014686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42014686

Download JSON
Disease
type 2 diabetes mellitus613 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial.
PubMed
Journal
Nat Commun
PubMed
Year
2026
PubMed
Publication types
Journal Article, Clinical Trial, Phase I
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Benzhydryl CompoundsMajor topic
Diabetes Mellitus, Type 2Major topic
GlucosidesMajor topic
Hypoglycemic AgentsMajor topic
ObesityMajor topic
ThiophenesMajor topic
Adult
Aged
Female
Humans
Male
Middle Aged
Area Under Curve
Drug Interactions
Sodium-Glucose Transporter 2 Inhibitors
Pyrazoles

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
INV-007625, AmericaBill and Melinda Gates Foundation (Bill & Melinda Gates Foundation)PubMed
CFH 2022- 2Z- 40917Capital Foundation of Medical Development (Capital Foundation of Medical Development of China)PubMed

Source PubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03790787Drug Interaction Study Between Dorzagliatin and EmpagliflozinDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129946963Empagliflozin: A Review in Type 2 Diabetes.Drugs2018https://conductscience.org/library/papers/29946963PubMed
237385967Diabetes remission in drug-naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study.Diabetes Obes Metab2023https://conductscience.org/library/papers/37385967PubMed
337356446Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.Lancet2023https://conductscience.org/library/papers/37356446PubMed
424463448Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.J Clin Invest2014https://conductscience.org/library/papers/24463448PubMed
534027215Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state.Arch Med Sci Atheroscler Dis2021https://conductscience.org/library/papers/34027215PubMed
638394489Efficacy and safety of dorzagliatin, a novel glucokinase activators, in the treatment of T2DM: A meta-analysis of randomized controlled trials.Medicine (Baltimore)2024https://conductscience.org/library/papers/38394489PubMed
734610719Assessment of Insulin Secretion and Insulin Resistance in Human.Diabetes Metab J2021https://conductscience.org/library/papers/34610719PubMed
833398164Mechanisms controlling pancreatic islet cell function in insulin secretion.Nat Rev Mol Cell Biol2021https://conductscience.org/library/papers/33398164PubMed
928862799Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach.Diabetes Obes Metab2018https://conductscience.org/library/papers/28862799PubMed
1035551294Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.Nat Med2022https://conductscience.org/library/papers/35551294PubMed
1111147781Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity.Diabetes2001https://conductscience.org/library/papers/11147781PubMed
12380785909. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.Diabetes Care2024https://conductscience.org/library/papers/38078590PubMed
1332035116Progression of insulin resistance: A link between risk factors and the incidence of diabetes.Diabetes Res Clin Pract2020https://conductscience.org/library/papers/32035116PubMed
14376226632023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.Eur Heart J2023https://conductscience.org/library/papers/37622663PubMed
1524651807The oral minimal model method.Diabetes2014https://conductscience.org/library/papers/24651807PubMed
1630191186User's guide to correlation coefficients.Turk J Emerg Med2018https://conductscience.org/library/papers/30191186PubMed
1733822469Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide.Diabetes Obes Metab2021https://conductscience.org/library/papers/33822469PubMed
1831424428β Cell dysfunction during progression of metabolic syndrome to type 2 diabetes.J Clin Invest2019https://conductscience.org/library/papers/31424428PubMed
1925554070Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.Diabetes Metab2014https://conductscience.org/library/papers/25554070PubMed
2025274537Empagliflozin: a review of its use in patients with type 2 diabetes mellitus.Drugs2014https://conductscience.org/library/papers/25274537PubMed

See all 35 referencesDownload CSV of references

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GCK2645PubTator's text mininghttps://conductscience.org/library/genes/2645NCBI Gene
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene
SLC5A26524PubTator's text mininghttps://conductscience.org/library/genes/6524NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
EMPAGLIFLOZINCHEMBL2107830Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2107830ChEMBL
DORZAGLIATINCHEMBL4297508Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4297508ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Cited by
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42014686

GET https://conductscience.org/api/papers/v1/42014686/references?page=2